Skip to main content

Tal Kafri, MD, PhD, is a UNC Lineberger Comprehensive Cancer Center member and Associate Professor of Microbiology and Immunology within the Gene Therapy Center at UNC-Chapel Hill School of Medicine. Kafri Lab is focused on the development of HIV-1 vectors for gene therapy of genetic and acquired human diseases, including hemophilia, Krabbe disease, and prostate cancer.

UNC-Chapel Hill

Area of interest

My research is focused on the development of lentiviral vectors for gene therapy applications and as a means to study HIV-1 biology. We put emphasis on improving the efficacy and safety of lentiviral vectors. Specifically, we seek to minimize adverse effects associated with lentiviral vector transduction including, insertional mutagenesis and vector mobilization. To this end we develop integration deficient vectors as well as vector carrying expression cassettes in opposite orientation. To facilitate vector production we develop stable packaging cell lines. To personalize gene delivery by lentiviral vectors, we employ the collaborative cross mouse strains panel to identify host factors that affect the efficacy and safety of lentiviral vectors.

Find publications on PubMed